Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

被引:131
作者
Okusaka, T
Ishii, H
Funakoshi, A
Yamao, K
Ohkawa, S
Saito, S
Saito, H
Tsuyuguchi, T
机构
[1] Natl Canc Ctr, Hepatobiliary & Pancreat Oncol Div, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr Hosp, Chiba, Japan
[3] Kyushu Natl Canc Ctr, Fukuoka, Japan
[4] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
[5] Kanagawa Canc Ctr Hosp, Yokohama, Kanagawa, Japan
[6] Aomori Prefectural Cent Hosp, Aomori, Japan
[7] Yamagata Prefectural Cent Hosp, Yamagata, Japan
[8] Chiba Univ Hosp, Chiba, Japan
关键词
biliary tract cancer; chemotherapy; clinical trial; gallbladder cancer; gemcitabine;
D O I
10.1007/s00280-005-0095-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This phase II study was conducted to evaluate the efficacy and toxicity of single-agent gemcitabine in patients with advanced or metastatic biliary tract cancer. Patients and methods: Gemcitabine 1,000 mg/m(2) was administered as an intravenous 30-min infusion on days 1, 8, and 15 for every 28 days. Results: Forty chemonaive patients with a median age of 61 (range 33-73) were enrolled, and all 40 patients were involved in efficacy and safety analyses. Seven (17.5%) achieved partial response; 15 (37.5%) had stable disease; 17 (42.5%) had progressive disease; and 1 (2.5%) was not evaluated. The median survival time was 7.6 months, and the 1-year survival rate was 25.0%. Grade 3/4 neutropenia occurred in 12 patients (30.0%), leukopenia in five patients (12.5%), and anemia in four patients (10.0%). The most common grade 3/4 nonhematologic toxicities were elevated ALT (15.0%) and elevated gamma-GTP ( 12.5%). One patient had grade 4 hemolytic uremic syndrome and recovered after discontinuation of gemcitabine. Conclusions: In single-agent therapy, gemcitabine demonstrated moderate efficacy with manageable toxicity in patients with advanced or metastatic biliary tract cancer. Further evaluations are warranted, including the exact impact of gemcitabine on the management of advanced or metastatic biliary tract cancer.
引用
收藏
页码:647 / 653
页数:7
相关论文
共 44 条
[1]  
AABO K, 1985, CANCER TREAT REP, V69, P449
[2]  
AGELAKI S, 1999, P AN M AM SOC CLIN, V18, pA276
[3]  
[Anonymous], 1999, COMM TOX CRIT VERS 2
[4]  
ARROYO G, 2001, P AN M AM SOC CLIN, V20, pA157
[5]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[6]   Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas [J].
Chen, JS ;
Lin, YC ;
Jan, YY ;
Liau, CT .
ANTI-CANCER DRUGS, 2001, 12 (04) :339-343
[7]  
DAVIS HL, 1974, CANCER, V33, P193, DOI 10.1002/1097-0142(197401)33:1<193::AID-CNCR2820330128>3.0.CO
[8]  
2-S
[9]  
Dobrila-Dintinjana R., 2000, American Journal of Gastroenterology, V95, P2476
[10]   Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin [J].
Ducreux, M ;
Rougier, P ;
Fandi, A ;
Clavero-Fabri, MC ;
Villing, AL ;
Fassone, F ;
Fandi, L ;
Zarba, J ;
Armand, JP .
ANNALS OF ONCOLOGY, 1998, 9 (06) :653-656